Izokibep: Preclinical development and first-in-human study of a novel IL-17A neutralizing Affibody molecule in patients with plaque psoriasis

• Main Authors: Susanne Klint (Author), Joachim Feldwisch (Author), Lindvi Gudmundsdotter (Author), Karin Dillner Bergstedt (Author), Elin Gunneriusson (Author), Ingmarie Höidén Guthenberg (Author), Anders Wennborg (Author), Andrew C. Nyborg (Author), Amol P. Kamboj (Author), Paul M. Peloso (Author), David Bejker (Author), Fredrik Y. Frejd (Author)
• Format: Book
• Published: Taylor & Francis Group, 2023-12-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

ABSTRACTPsoriasis, an immune-mediated inflammatory disease, affects nearly 125 million people globally. The interleukin (IL)-17A homodimer is a key driver of psoriasis and other autoimmune diseases, including psoriatic arthritis, axial spondyloarthritis, hidradenitis suppurativa, and uveitis. Treatm...